BioCentury | Mar 6, 2021
Deals

How Bayer is building a cell and gene therapy business through deals

After spending the last year laying the groundwork for its entrance into cell and gene therapies through dealmaking, Bayer is expanding its external innovation search to new indications and earlier-stage...
BioCentury | Mar 6, 2021
Finance

With $106M series C, Tenaya will bring AAV manufacturing in-house

With $106 million in new series C funding, Tenaya will internalize its AAV manufacturing capabilities and continue to advance its suite of gene therapy, cellular regeneration and precision medicine platforms for heart disease.  Tenaya Therapeutics...
BioCentury | Mar 5, 2021
Product Development

March 4 COVID Quick Takes: More guidance on vaccines for variants; plus EMA begins review of Sputnik V, Novartis-CureVac, Bharat-Ocugen, Novavax and more

The ACCESS consortium, a coalition of regulatory authorities from the U.K., Australia, Canada, Singapore and Switzerland, released guidance on Thursday outlining the data needed to approve variant-specific modifications to authorized COVID-19 vaccines. According to the guidance, immunogenicity...
BioCentury | Mar 5, 2021
Translation in Brief

A stem cell therapy for brain metastases in breast cancer; plus a nanoparticle gene editing delivery tech and more

A team led by Khalid Shah from Harvard Medical School engineered allogeneic stem cells with an anti-EGFR camelid antibody fused to a death receptor ligand. Published in Science Advances, the therapy induced apoptosis of cancer...
BioCentury | Mar 3, 2021
Product Development

FDA seeks to dampen expectations on BrainStorm ALS therapy amid patient push for access

In the face of a social media campaign by patients advocating for the access to BrainStorm’s ALS therapy NurOwn, FDA took the highly unusual step of commenting on the results of a Phase III...
BioCentury | Feb 27, 2021
Emerging Company Profile

Orna: turning circular RNAs into therapies

Orna emerged from stealth Wednesday with an $80 million A round to develop circular RNA therapies for cancer and genetic diseases that could be easier to manufacture than linear RNAs and immune cell therapies. MPM Capital,...
BioCentury | Feb 27, 2021
Translation in Brief

A $53M UC Berkeley-UCSF-Genentech-Roche collaboration on brain diseases; plus Selecta, JDRF-Harvard Stem Cell Institute, Tissue Dynamics and more

University of California Berkeley and University of California San Francisco announced Thursday a research collaboration with Genentech Inc. and Roche (SIX:ROG; OTCQX:RHHBY) to develop therapies for CNS disorders. The universities will receive up to $53 million...
BioCentury | Feb 17, 2021
Finance

CRISPR stocks begin to converge in the clinic: Data Byte

CRISPR Therapeutics’ stock price is still more than twice that of its closest gene editing peers, but the picture has started to shift over the past year as other companies have entered the clinic.  CRISPR...
BioCentury | Feb 17, 2021
Management Tracks

Athersys chair Gil Van Bokkelen steps down; plus Strongbridge, Medical Alley Association, Freeline, AlzeCure, Egetis, Arena and Prime Movers

Regenerative medicine company Athersys Inc. (NASDAQ:ATHX) said Chairman and CEO Gil Van Bokkelen has stepped down. While the company searches for a successor, President and COO William Lehmann will be interim CEO. Ismail Kola, a...
BioCentury | Feb 16, 2021
Deals

Feb. 16 Quick Takes: Cytovia, Cellectis partner on TALEN-edited NK cells; plus Cend-Qilu, Iterion and Woodford

Cytovia Therapeutics Inc. and Cellectis S.A. (Euronext:ALCLS; NASDAQ:CLLS) began a strategic R&D collaboration to develop induced pluripotent stem cell-derived NK and CAR-NK cell therapies using TALEN gene editing. Cellectis will receive $15 million in Cytovia equity...
Items per page:
1 - 10 of 7471
BioCentury | Mar 6, 2021
Deals

How Bayer is building a cell and gene therapy business through deals

After spending the last year laying the groundwork for its entrance into cell and gene therapies through dealmaking, Bayer is expanding its external innovation search to new indications and earlier-stage...
BioCentury | Mar 6, 2021
Finance

With $106M series C, Tenaya will bring AAV manufacturing in-house

With $106 million in new series C funding, Tenaya will internalize its AAV manufacturing capabilities and continue to advance its suite of gene therapy, cellular regeneration and precision medicine platforms for heart disease.  Tenaya Therapeutics...
BioCentury | Mar 5, 2021
Product Development

March 4 COVID Quick Takes: More guidance on vaccines for variants; plus EMA begins review of Sputnik V, Novartis-CureVac, Bharat-Ocugen, Novavax and more

The ACCESS consortium, a coalition of regulatory authorities from the U.K., Australia, Canada, Singapore and Switzerland, released guidance on Thursday outlining the data needed to approve variant-specific modifications to authorized COVID-19 vaccines. According to the guidance, immunogenicity...
BioCentury | Mar 5, 2021
Translation in Brief

A stem cell therapy for brain metastases in breast cancer; plus a nanoparticle gene editing delivery tech and more

A team led by Khalid Shah from Harvard Medical School engineered allogeneic stem cells with an anti-EGFR camelid antibody fused to a death receptor ligand. Published in Science Advances, the therapy induced apoptosis of cancer...
BioCentury | Mar 3, 2021
Product Development

FDA seeks to dampen expectations on BrainStorm ALS therapy amid patient push for access

In the face of a social media campaign by patients advocating for the access to BrainStorm’s ALS therapy NurOwn, FDA took the highly unusual step of commenting on the results of a Phase III...
BioCentury | Feb 27, 2021
Emerging Company Profile

Orna: turning circular RNAs into therapies

Orna emerged from stealth Wednesday with an $80 million A round to develop circular RNA therapies for cancer and genetic diseases that could be easier to manufacture than linear RNAs and immune cell therapies. MPM Capital,...
BioCentury | Feb 27, 2021
Translation in Brief

A $53M UC Berkeley-UCSF-Genentech-Roche collaboration on brain diseases; plus Selecta, JDRF-Harvard Stem Cell Institute, Tissue Dynamics and more

University of California Berkeley and University of California San Francisco announced Thursday a research collaboration with Genentech Inc. and Roche (SIX:ROG; OTCQX:RHHBY) to develop therapies for CNS disorders. The universities will receive up to $53 million...
BioCentury | Feb 17, 2021
Finance

CRISPR stocks begin to converge in the clinic: Data Byte

CRISPR Therapeutics’ stock price is still more than twice that of its closest gene editing peers, but the picture has started to shift over the past year as other companies have entered the clinic.  CRISPR...
BioCentury | Feb 17, 2021
Management Tracks

Athersys chair Gil Van Bokkelen steps down; plus Strongbridge, Medical Alley Association, Freeline, AlzeCure, Egetis, Arena and Prime Movers

Regenerative medicine company Athersys Inc. (NASDAQ:ATHX) said Chairman and CEO Gil Van Bokkelen has stepped down. While the company searches for a successor, President and COO William Lehmann will be interim CEO. Ismail Kola, a...
BioCentury | Feb 16, 2021
Deals

Feb. 16 Quick Takes: Cytovia, Cellectis partner on TALEN-edited NK cells; plus Cend-Qilu, Iterion and Woodford

Cytovia Therapeutics Inc. and Cellectis S.A. (Euronext:ALCLS; NASDAQ:CLLS) began a strategic R&D collaboration to develop induced pluripotent stem cell-derived NK and CAR-NK cell therapies using TALEN gene editing. Cellectis will receive $15 million in Cytovia equity...
Items per page:
1 - 10 of 7471